202 study allowed alterity to monitor and observe the advanced pts and alter treatment if need be, which they did not need too from the safety advisor committee.
201 study are all newly diagnosed MSA pts, and all were placed into 3 cohorts, one given placebo, second given lower dose, third cohort larger dose.
Once all information gathered, they get to see which cohort was which, and who outperformed who, and if there were any changes.
Therefore they have no idea who gets what until the end, only those dispensing the medication know who is who.
For example I treated a pt several weeks back who was on a trial, and not even the Dr knew what drug he was being given.
Ann: Alterity Data Presentations at MDS Congress Raises Profile, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $88.06K | 8.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 11330464 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1574126 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |